New York, NY -- (SBWIRE) -- 01/13/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX), Baltic Trading Ltd (NYSE:BALT), IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), Response Genetics, Inc (NASDAQ:RGDX)
Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) showed a volume of 1.74 million shares by the end of last trade whereas the average volume of the stock remained 1.43 million shares. The stock opened the session at $1.86 but then moved to $2.00. At that price, the stock showed a positive performance of 8.70%. Lexicon Pharmaceuticals, Inc. (Lexicon Pharmaceuticals) is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon Pharmaceuticals uses its gene knockout technologies and an integrated platform of medical technologies to study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as drug targets.
Will LXRX Continue To Move Higher? Find Out Here
Baltic Trading Ltd (NYSE:BALT) opened the session at $5.90 and closed the session at $6.17. The stock showed a positive performance of 0.33% in previous trading session. Traded with volume of 1.71 million shares in the prior session and the average volume of the stock remained 1.27 million shares. Baltic Trading Limited conducts shipping business focused on the drybulk industry spot market. The Company was formed by Genco Shipping & Trading Limited (Genco), an international drybulk shipping company. The Company’s fleet consists of two Capesize vessels, four Supramax vessels and three Handysize vessels with an aggregate carrying capacity of approximately 672,000 deadweight tons. Its fleet contains three groups of sister ships, which are vessels of virtually identical sizes and specifications.
For How Long BALT will fight for Profitability? Read This Trend Analysis report
IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) opened the session at $3.72 and closed the session at $3.90. The stock showed a positive performance of 5.98% in previous trading session. Traded with volume of 1.69 million shares in the prior session and the average volume of the stock remained 694,021.00 shares. The beta of the stock remained 1.23. Intellipharmaceutics International Inc. (IPC) is a pharmaceutical company specializing in the research, development and manufacture of generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technologies are a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a range of existing and new pharmaceuticals. Based on its technologies,
Why Should Investors Buy IPCI After The Recent Gain? Just Go Here and Find Out
Response Genetics, Inc (NASDAQ:RGDX) the stock advanced 13.87% and finished the session at $1.56. Traded with volume of 1.69 million shares in the prior session and the average volume of the stock remained 334,594.00 shares. The beta of the stock remained 0.42. Response Genetics, Inc. is a life sciences company engaged in the research and development of clinical diagnostic tests for cancer. The Company generates revenues primarily from sales of its ResponseDX diagnostic tests. It focuses on commercialization of its ResponseDX tests; developing additional diagnostic tests for assessing the risk of cancer recurrence, prediction of chemotherapy response and tumor classification in cancer patients, and expanding its testing services business by pursuing new technologies through collaborations and in-licensing to expand its business.
Will RGDX Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)